Study of Recombinant Human Insulin-Like Growth Factor I in Patients With Severe Insulin Resistance

Completed · Not applicable

Conditions studied: Insulin Resistance, Hyperglycemia

In brief

OBJECTIVES: I. Determine the efficacy and toxic effects of recombinant human insulin-like growth factor I (rhIGF-I) on carbohydrate tolerance, insulin action, insulin secretion, hyperandrogenism, and hyperlipidemia in patients with severe insulin resistance who have failed other therapies. II. Determine the dose and time response of rhIGF-I on carbohydrate homeostasis and secondary abnormalities in this patient population. III. Determine the effect of rhIGF-I on insulin clearance, the regulation of insulin-like growth factor binding protein 1, the regulation of sex hormone binding globulin, and hypothalamic pituitary gonadal axis in this patient population.

Key facts

Study ID
NCT00004419
Run by
Beth Israel Deaconess Medical Center
People needed
18
Starts
1998-04-01
Expected to finish
2000-09-01
Last updated by the study team
2015-03-25

Who can join

Age: 14 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.